Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Hippen KL, Bucher C, Schirm DK, Bearl AM, Brender T, Mink KA, Waggie KS, Peffault de Latour R, Janin A, Curtsinger JM, Dillon SR, Miller JS, Socie G, Blazar BR.

Blood. 2012 Jan 12;119(2):619-28. doi: 10.1182/blood-2011-07-368027. Epub 2011 Nov 10.

2.

IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation.

Bucher C, Koch L, Vogtenhuber C, Goren E, Munger M, Panoskaltsis-Mortari A, Sivakumar P, Blazar BR.

Blood. 2009 Dec 17;114(26):5375-84. doi: 10.1182/blood-2009-05-221135. Epub 2009 Oct 20.

3.

IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.

Szebeni J, Wang MG, Pearson DA, Szot GL, Sykes M.

Transplantation. 1994 Dec 27;58(12):1385-93.

PMID:
7809932
4.

In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease.

Chiang EY, Kolumam G, McCutcheon KM, Young J, Lin Z, Balazs M, Grogan JL.

PLoS One. 2012;7(3):e33106. doi: 10.1371/journal.pone.0033106. Epub 2012 Mar 12.

5.

Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.

Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJ.

Blood. 2015 Feb 26;125(9):1502-6. doi: 10.1182/blood-2014-10-603449. Epub 2014 Nov 26.

6.

Critical role of interleukin-2 in the development of acute graft-versus-host disease.

Via CS, Finkelman FD.

Int Immunol. 1993 Jun;5(6):565-72.

PMID:
8102248
7.
8.

Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-γ/IL-17-producing cells.

Okamoto S, Fujiwara H, Nishimori H, Matsuoka K, Fujii N, Kondo E, Tanaka T, Yoshimura A, Tanimoto M, Maeda Y.

J Immunol. 2015 Feb 1;194(3):1357-63. doi: 10.4049/jimmunol.1400973. Epub 2014 Dec 19.

9.

Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.

Hatano R, Ohnuma K, Yamamoto J, Dang NH, Yamada T, Morimoto C.

Br J Haematol. 2013 Jul;162(2):263-77. doi: 10.1111/bjh.12378. Epub 2013 May 21.

PMID:
23692598
10.

Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute graft-versus-host disease.

Saito K, Yagita H, Hashimoto H, Okumura K, Azuma M.

Eur J Immunol. 1996 Dec;26(12):3098-106.

PMID:
8977310
11.

Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).

Cao T, Soto A, Zhou W, Wang W, Eck S, Walker M, Harriman G, Li L.

Cell Immunol. 2009;258(1):65-71. doi: 10.1016/j.cellimm.2009.03.013. Epub 2009 May 1.

PMID:
19410243
12.

IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.

Koenecke C, Lee CW, Thamm K, Föhse L, Schafferus M, Mittrücker HW, Floess S, Huehn J, Ganser A, Förster R, Prinz I.

J Immunol. 2012 Sep 15;189(6):2890-6. doi: 10.4049/jimmunol.1200413. Epub 2012 Aug 6.

13.

Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells.

Park MJ, Moon SJ, Lee SH, Yang EJ, Min JK, Cho SG, Yang CW, Park SH, Kim HY, Cho ML.

PLoS One. 2013 Jun 20;8(6):e67171. doi: 10.1371/journal.pone.0067171. Print 2013.

14.

Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD.

Hechinger AK, Smith BA, Flynn R, Hanke K, McDonald-Hyman C, Taylor PA, Pfeifer D, Hackanson B, Leonhardt F, Prinz G, Dierbach H, Schmitt-Graeff A, Kovarik J, Blazar BR, Zeiser R.

Blood. 2015 Jan 15;125(3):570-80. doi: 10.1182/blood-2014-06-581793. Epub 2014 Oct 28.

16.

Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.

Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB.

Clin Cancer Res. 2006 Sep 15;12(18):5520-5.

17.

Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.

Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, Andrè V, Todisco E, Rahal D, Migliavacca M, Longoni D, Solinas G, Villa A, Berti E, Mina PD, Parma M, Allavena P, Biagi E, Rovelli A, Biondi A, D'Amico G.

Transplantation. 2009 Dec 15;88(11):1261-72. doi: 10.1097/TP.0b013e3181bc267e.

PMID:
19996925
18.

Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.

Pillai AB, George TI, Dutt S, Strober S.

Blood. 2009 Apr 30;113(18):4458-67. doi: 10.1182/blood-2008-06-165506. Epub 2009 Feb 12.

19.

Interferon-gamma is not involved in the intestinal manifestations of the acute murine semiallogenic graft-versus-host disease.

Stüber E, Schlenger P, Von Freier A, Arendt T, Fölsch UR.

Int J Colorectal Dis. 2001 Sep;16(5):346-51.

PMID:
11686535
20.

Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.

Chen X, Chang CH, Stein R, Cardillo TM, Gold DV, Goldenberg DM.

Biol Blood Marrow Transplant. 2013 Jan;19(1):28-39. doi: 10.1016/j.bbmt.2012.09.015. Epub 2012 Sep 28.

Supplemental Content

Support Center